Demographics and baseline characteristics of Study 1 (ITT Analysis Set).
respiratory syncytial virus, nasal aspirate
BMI, body mass index; IQR, interquartile range; ITT, intent-to-treat; MAD, multiple-ascending dose; NHOP, Native Hawaiian or Other Pacific Islander; RSV, respiratory syncytial virus; SAD, single-ascending dose; SD, standard deviation.In the SAD study phase, 45 (lumicitabine: 35 [66.0%]; placebo: 10 [58.8%]) patients were positive for RSV-A, 23 (lumicitabine: 16 [30.2%]; placebo: 7 [41.2%]) patients were positive for RSV-B, and 2 (3.8%) patients from the lumicitabine groups were positive for both RSV-A and RSV-B. The median viral load at the baseline was 5.58 logIn the MAD study phase, for patients with nasal aspirate, 33 (lumicitabine: 24 [57.1%]; placebo: 9 [45.0%]) patients were positive for RSV-A, 28 (lumicitabine: 18 [42.9%]; placebo: 10 [50.0%]) patients were positive for RSV-B, and 1 (5.0%) patient from the placebo group was positive for both RSV-A and RSV-B. For patients with nasal swabs, 29 (lumicitabine: 24 [70.6%]; placebo: 5 [41.7%]) patients were positive for RSV-A and 17 (lumicitabine: 10 [29.4%]; placebo: 7 [58.3%]) patients were positive for RSV-B. The median viral load at the baseline for the overall lumicitabine groups was 5.71 logIn Study 2, all 7 patients were of Asian origin, the median age was 9 months, with most being male (n = 6, 85.7%). Mean duration of RSV symptoms from onset to time of randomization was 3.6 days. The median viral load at the baseline was 7.8 log